Monosaccharide-based antimetabolites: 2-Deoxy-D-glucose and 2-DG analogs as potential anticancer agents

CARB 36

Waldemar Priebe, wp@wt.net, Department of Experimental Therapeutics, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd, Unit 0422, Houston, TX 77030-1402
We have demonstrated significant activity of 2-deoxy-D-glucose (2-DG) and its analogs in chemotherapeutically resistant tumors of the brain and pancreas. Inhibition of tumor cell growth can occur under hypoxia or normoxia by interfering directly with monosaccharide metabolism. 2-Halo-substituted derivatives of D-glucose and D-mannose were synthesized and a comparison of their biological properties indicated with increase size of the substituted halogen (i.e. F > Cl > Br) D-glucose derivatives became less effective in inhibiting growth under aerobic vs. hypoxic conditions. Moreover, 2-deoxy-2-fluoro-D-glucose shows better activity than 2-DG in our assays. Additionally, the change in orientation of the fluorine atom from D-gluco to D-manno configuration does not significantly alter the growth inhibitory activity. Overall, our results suggest that monosaccharide-based antimetabolites such as 2-DG and 2-FG will be useful clinically in selectively targeting glycolytic tumor cells.
 

Sugar Alley Symposium
8:30 AM-12:10 PM, Tuesday, April 8, 2008 Morial Convention Center -- Rm. 223, Oral

Division of Carbohydrate Chemistry

The 235th ACS National Meeting, New Orleans, LA, April 6-10, 2008